Application

Products for Diagnostics

 
Applications in Diagnostics


Precision and consistency of results are vital but diagnostic stabilizer reagents continue to be an issue. Performance failures and inaccurate results are derived from defective components, perishable reagents and chemical reagent inconsistencies. Even more challenges arise when animal or human-derived blocking agents are used.

InVitria has designed diagnostic stabilizer reagents containing animal-free, recombinant albumin that specifically address the common problems faced in diagnostics.

Typical Assay Problems

Invitria Diagnostic Reagents

Lack of specificity

Significantly improve specificity

Cross reactivity and non-specific binding

Reduce non-specific binding and eliminate cross reactivity

Unstable protein or biomarker

Stabilize a sensitive protein or biomarker

Poor reagent consistency

Ensure better performance and consistent results

Variability in animal- and human-derived components

Protease Free!

Outperform products such as BSA and human serum albumin from plasma

Occupational safety risk of using animal or human blood products

Eliminates occupational safety risk and regulatory concerns

  

How InVitria’s Diagnostic Reagents Work

Recombinant Albumin-DX and Albumin-DX (Lipid-Reduced) both contain a recombinant albumin produced in an animal component free production system. Highly purified, IgG-free and consistent, reducing non-specific binding and cross reactivity while maintaining the integrity of sensitive diagnostic biomarkers and proteins.

 
  • Blog: The Cell Culture Dish

    Cell Culture Media supplement Blog Strategies for Improving Viral Yield in Vaccine Manufacturing

    A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More

  • Latest News

    Invitria Cell Culture Media News InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference

    March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more